Literature DB >> 16292678

Obtaining hyperimmune anti-Cryptosporidium parvum ovine colostrum. A study of the humoral immune response in immunized sheep.

S Martín-Gómez1, M A Alvarez-Sánchez, F A Rojo-Vázquez.   

Abstract

Three ewes were immunized five times over a 2-month period prior to giving birth by intramuscular injection, oral administration and intramammary infusion of antigen and viable or freeze-dried Cryptosporidium parvum oocyst solution emulsified with Freund's complete and incomplete adjuvant. Two animals served as controls and another two as adjuvant controls. Serum was collected at first immunization and thereafter every 2 to 4 weeks. Colostrum and milk were collected as well. All samples were assayed for C. parvum-specific antibodies using an enzyme-linked immunosorbent assay methodology, and Western blotting was used to recognize the C. parvum antigens. Hyperimmunization resulted in a progressive and significant increase in specific anti-C. parvum serum IgG, IgA and IgM titres, with the highest values noted at the point of lambing. Titres decreased slightly in milk, although they were in all cases higher than those in the control animals. Moreover, some 30 bands of C. parvum were recognized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16292678     DOI: 10.1007/s00436-005-0031-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  29 in total

1.  Characterization of a high molecular weight antigen of Cryptosporidium parvum micronemes possessing epitopes that are cross-reactive with all parasitic life cycle stages.

Authors:  B Robert; H Antoine; F Dreze; P Coppe; A Collard
Journal:  Vet Res       Date:  1994       Impact factor: 3.683

2.  Isolation of Cryptosporidium oocysts and sporozoites using discontinuous sucrose and isopycnic Percoll gradients.

Authors:  M J Arrowood; C R Sterling
Journal:  J Parasitol       Date:  1987-04       Impact factor: 1.276

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 4.  Cryptosporidium and cryptosporidiosis in man and animals.

Authors:  P J O'Donoghue
Journal:  Int J Parasitol       Date:  1995-02       Impact factor: 3.981

5.  Protection of calves against cryptosporidiosis with immune bovine colostrum induced by a Cryptosporidium parvum recombinant protein.

Authors:  L E Perryman; S J Kapil; M L Jones; E L Hunt
Journal:  Vaccine       Date:  1999-04-23       Impact factor: 3.641

6.  Immunotherapeutic efficacy of bovine colostral immunoglobulins from a hyperimmunized cow against cryptosporidiosis in neonatal mice.

Authors:  R Fayer; A Guidry; B L Blagburn
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

7.  Protection of calves with a vaccine against Cryptosporidium parvum.

Authors:  J A Harp; J P Goff
Journal:  J Parasitol       Date:  1995-02       Impact factor: 1.276

8.  Anti-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo.

Authors:  P S Doyle; J Crabb; C Petersen
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Age-related resistance in ovine cryptosporidiosis: patterns of infection and humoral immune response.

Authors:  L M Ortegà-Mora; S E Wright
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

View more
  1 in total

1.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.